CYP19A1 and Arthralgia: As aromatase inhibitors are more frequently used as endocrine therapy in women above age 60 years compared to younger women, the observed exercise effect on skeletal symptoms might be attributed to mitigation of aromatase inhibitor induced arthralgia, as has been suggested by previous studies.40